Daily Medication Pearl: Glecaprevir and Pibrentasvir (Mavyret) for Hepatitis C

Mavyret is indicated for the treatment of patients with chronic hepatitis C virus without cirrhosis or with compensated cirrhosis.

Medication Pearl of the Day: Glecaprevir and Pibrentasvir (Mavyret)

Indication: Mavyret is a fixed-dose combination of glecaprevir and pibrentasvir, indicated for the treatment of adult and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype (GT) 1, 2, 3, 4, 5 or 6 infections without cirrhosis or with compensated cirrhosis.

Insight:

  • Dosing: Three tablets taken at the same time orally once daily (total daily dose: glecaprevir 300 mg and pibrentasvir 120 mg) with food.
  • Dosage form: Tablets 100 mg glecaprevir and 40 mg pibrentasvir. Oral pellets 50 mg glecaprevir and 20 mg pibrentasvir.
  • Adverse events (AEs): In patients receiving Mavyret, the most reported AEs (greater than 10%) are headache and fatigue.
  • Mechanism of action: Mavyret is a fixed-dose combination of glecaprevir, an HCV NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor.
  • Manufacturer: AbbVie

Sources: